Plavix may not be effectively metabolized by up to 14 percent of users making the blockbuster anti-clot drug useless and putting patients at an increased risk of heart attack and stroke. The FDA will require a black box warning on the drug, the most severe warning the FDA can require.
The gold standard blood-thinners, used for heart attack and stroke, may be rivaled by an experimental drug, Brilinta, which causes less bleeding and increases the chance of survival.
New recommendations by the U.S. Preventive Services Task Force suggest low doses of aspirin daily are just as effective as higher doses and safer at preventing a first heart attack in men and first stroke in women.
Today the FDA notified healthcare professionals that Plavix, (clopidogrel bisulfate) is less effective in preventing blood clots in some patients than others and it will try and determine whether the differences are due to genetic factors or mixing Plavix with other drugs. The news comes after studies found that the blockbuster drug had mixed reviews on effectiveness.
Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery. We are committed to serving the public with honesty and integrity in these efforts.
On the Road
Major Medical
Protecting Your Family
In the Workplace
Motley Rice Ranked A Best Law Firm by U.S. News and World Report
Tampa Toddler Dies After Being Left In Vehicle
Burn Advocates Network Returns From Mission In Haiti
Update: Burn Advocates Network In Haiti
Burn Advocates Network In Haiti